SCHEMBL4369801

SCHEMBL4369801

Cc1nc2ccc(F)cc2c(=O)[nH]1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYMS P04818 3/20 0.72
KDM4E B2RXH2 2/20 0.62
HSD17B10 Q99714 2/20 0.62
LMNA P02545 1/20 0.62
PARP1 P09874 7/20 0.59
TNKS2 Q9H2K2 5/20 0.59
NPC1 O15118 1/20 0.58
USP2 O75604 1/20 0.58
ALDH1A1 P00352 1/20 0.58
GLA P06280 1/20 0.58
GAA P10253 1/20 0.58
MAPT P10636 1/20 0.58
HPGD P15428 1/20 0.58
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
IP6K1 Q92551 1/20 0.57
POLB P06746 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
TNKS O95271 4/20 0.56
TUBB4A P04350 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4878797 0.86 TYMS (0.63) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL6652380 0.84 TYMS (1.00) TYMSPARP1
SCHEMBL12847208 0.82 HSD17B10 (0.60) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL29535139 0.82 KDM4E (0.66) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL7263029 0.82 KDM4E (0.66) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL31079885 0.82 TUBB4A (0.57) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL31463101 0.79 TYMS (0.72) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL6014177 0.79 TYMS (0.72) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL5313776 0.79 TYMS (0.72) TYMSKDM4EHSD17B10LMNAPARP1
SCHEMBL3115005 0.79 TYMS (0.72) TYMSKDM4EHSD17B10LMNAPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119954731-A Chalcone derivative containing 4-quinazolinone structure, and preparation method and application thereof 黔南州烟草公司平塘县分公司 2025-05-09 CN disclosed
EP-2935246-B1 ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC (US) 2018-07-25 EP disclosed
US-9951029-B2 Styryl quinazoline derivatives as pharmaceutically active agents VICHEM CHEMIE KUTATÓ KFT. (HU) 2018-04-24 US disclosed
EP-3008053-B1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD CALISTOGA LLC (US) 2018-03-21 EP disclosed
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS VICHEM CHEMIE KUTATÓ KFT. (HU) 2016-07-07 US disclosed
US-8183276-B2 Therapeutic agents MERCK SHARP & DOHME CORP. 2012-05-22 US disclosed
WO-2009046536-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) 2009-04-16 WO disclosed
WO-2009046536-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) 2009-04-16 WO disclosed
US-7410974-B2 Halogenated Quinazolinyl nitrofurans as antibacterial agents ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) 2008-08-12 US disclosed
US-7410974-B2 Halogenated Quinazolinyl nitrofurans as antibacterial agents ULYSSES PHARMACEUTICAL PRODUCTS, INC. (CA) 2008-08-12 US disclosed
US-20080188499-A1 Carbo- and Hetero-Cyclic Antibiotics and Use Thereof ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) 2008-08-07 US disclosed
US-20080146562-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS INC., 2008-06-19 US disclosed
US-20080146562-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS INC., 2008-06-19 US disclosed
US-20080146562-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS INC., 2008-06-19 US disclosed
CN-101027299-A Carbon-and hetero-cyclic nitrofuran antibiotics and use thereof ULYSSES PHARMACEUTICAL PRODUCT (CA) 2007-08-29 CN disclosed
EP-1660486-A4 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCT (CA) 2006-12-13 EP disclosed
US-20060258693-A1 Halogenated quinazolinyl nitrofurans as antibacterial agents ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) 2006-11-16 US disclosed
CN-1832941-A Halogenated quinazolinyl nitrofurans as antibacterial agents ULYSSES PHARMACEUTICAL PRODUCT (CA) 2006-09-13 CN disclosed
EP-1660486-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS Ulysses Pharmaceuticals Products Inc. (CA) 2006-05-31 EP disclosed
WO-2005014585-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS ULYSSES PHARMACEUTICAL PRODUCTS INC. (CA) 2005-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146562-A1 HALOGENATED QUINAZOLINYL NITROFURANS AS ANTIBACTERIAL AGENTS HRH3, HRH1, NQO2 TYMS 2570/4885KDM4E 3381/4885HSD17B10 532/4885
US-20080188499-A1 Carbo- and Hetero-Cyclic Antibiotics and Use Thereof SLC7A1, CYP2C19, ABCB11 TYMS 1031/4885KDM4E 3808/4885HSD17B10 334/4885
US-20060258693-A1 Halogenated quinazolinyl nitrofurans as antibacterial agents C1S, HRH1, NQO2 TYMS 2118/4885KDM4E 3941/4885HSD17B10 511/4885
US-20160194291-A1 STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS FLT3, BCR, STK3 TYMS 231/4885KDM4E 4561/4885HSD17B10 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.